A breakthrough in malaria vaccines has the potential to prevent millions of cases. Read more...
Vaccine projectsWe strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.
Evaluation technology projectsWe partner to develop and optimize new assays and challenge models and support reference and service laboratories. Find out more about our evaluation technologies by clicking on each project box below.
RTS,SThe World Health Organization (WHO) has issued a position paper for GSK's malaria vaccine candidate RTS,S (also known as MosquirixTM).
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy
26 Feb 2016